Jacob M. Chacko, M.D., serves as the President and Chief Executive Officer at ORIC Pharmaceuticals Inc., a clinical-stage biopharmaceutical company focused on developing treatments for various cancers. Dr. Chacko brings a wealth of experience in the biopharma industry, having held leadership roles at several prominent companies. Prior to joining ORIC Pharmaceuticals, he was the President and CEO of Prothena Corporation, where he led the company's transformation into a clinical-stage biotechnology firm focused on protein misfolding diseases. Under his leadership, Prothena successfully advanced multiple programs into clinical development and secured significant partnerships. Before his tenure at Prothena, Dr. Chacko served as the Chief Medical Officer at OncoGenex Pharmaceuticals, where he played a key role in the development of late-stage oncology therapeutics. His career also includes positions at ZymoGenetics and Amgen, where he contributed to the development of novel biologics and oncology drugs. Dr. Chacko's extensive experience in drug development, coupled with his strategic vision, has been instrumental in driving ORIC Pharmaceuticals' mission to discover and develop innovative cancer therapies. As President and CEO of ORIC Pharmaceuticals, Dr. Chacko oversees the company's overall strategy and operations, guiding the development of its pipeline of small molecule therapies targeting critical mechanisms in cancer biology. His leadership has been pivotal in advancing ORIC's lead programs into clinical trials and fostering collaborations with leading academic institutions and pharmaceutical companies. Dr. Chacko's dedication to improving patient outcomes through innovative science continues to shape ORIC Pharmaceuticals' growth and success in the oncology field.